Zydus Lifesciences Limited
ZYDUSLIFE
Rang in aandelen
#1746
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Aandeelprijs
$12.30
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$12.27B
Verandering (1 dag)
0.06%
Verandering (1 jaar)
8.33%
Land
IN
Handel Zydus Lifesciences Limited (ZYDUSLIFE)
Categorie
Healthcare
Aantal uitstaande aandelen voor Zydus Lifesciences Limited (ZYDUSLIFE)
Aantal uitstaande aandelen per June 2026: 1.01B
Volgens de laatste financiële rapporten en de aandelenkoers van Zydus Lifesciences Limited bedraagt het huidige aantal uitstaande aandelen 1.01B. Aan het einde van March 2024 had het bedrijf 1.01B uitstaande aandelen. Het aantal uitstaande aandelen wordt meestal beïnvloed door aandelensplitsingen en terugkoop van aandelen.
Geschiedenis van uitstaande aandelen van Zydus Lifesciences Limited (ZYDUSLIFE) van 2004 tot 2026
Uitstaande aandelen aan het einde van elk jaar
| Jaar | Uitstaande aandelen | Wijzigen |
|---|---|---|
| 2026 (TTM) | 1.01B | -0.12% |
| 2025 | 1.01B | -0.55% |
| 2024 | 1.01B | -0.37% |
| 2023 | 1.02B | -0.79% |
| 2022 | 1.02B | 0.00% |
| 2021 | 1.02B | 0.00% |
| 2020 | 1.02B | 0.00% |
| 2019 | 1.02B | 0.00% |
| 2018 | 1.02B | 0.00% |
| 2017 | 1.02B | 0.00% |
| 2016 | 1.02B | 0.00% |
| 2015 | 1.02B | 0.00% |
| 2014 | 1.02B | 0.00% |
| 2013 | 1.02B | 0.00% |
| 2012 | 1.02B | 0.00% |
| 2011 | 1.02B | 0.00% |
| 2010 | 1.02B | 0.00% |
| 2009 | 1.02B | 8.67% |
| 2008 | 942.10M | 0.00% |
| 2007 | 942.10M | 0.00% |
| 2006 | 942.10M | 100.00% |
| 2005 | 471.05M | 0.00% |
| 2004 | 471.05M | 0.00% |
Uitstaande aandelen van vergelijkbare bedrijven of concurrenten
| Bedrijf | Uitstaande aandelen | Verschil | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 138.71% |
IN
|
